Alkermes to Report Third Quarter Financial Results on November 3, 2026Business Wire · 4 days ago
Alkermes to Report Third Quarter Financial Results on November 3, 2026GuruFocus · 4 days ago
Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to DeclineZacks Investment Research · 4 days ago
Alkermes plc $ALKS Shares Sold by State of Alaska Department of RevenueDefense World · 4 days ago
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine ResearchBusiness Wire · Oct 13, 2026
4 CNS Drug Stocks Worth Watching This World Mental Health DayZacks Investment Research · Oct 9, 2026Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 28, 2026 | -$0.03 | $0.70 | Beat |
| May 5, 2026 | -$0.57 | -$0.40 | Beat |
| Feb 25, 2026 | $0.43 | $0.34 | Miss |
| Oct 28, 2025 | $0.37 | $0.49 | Beat |
| Jul 29, 2025 | $0.41 | $0.52 | Beat |
| May 1, 2025 | $0.25 | $0.13 | Miss |